Jeff Hansen

Jeff Hansen

| This email address is being protected from spambots. You need JavaScript enabled to view it.

Research Editor

jeffhans@uab.edu • (205) 209-2355

Communicates UAB research discoveries and initiatives from across the university for a variety of audiences.

Specific beats include: biochemistry; cell, developmental and integrated biology; microbiology; molecular genetics; neurobiology; pathology; pharmacology and tocixology; Alabama Drug Discovery Alliance; Bill L. Harbert Institute for Innovation and Entrepreneurship.

This novel finding will help guide successful therapeutic design and strategies for acute kidney injury and chronic kidney disease.
Knockout of TXNIP improves diabetes-associated hyperglycemia and hyperglucagonemia.
The clinically approved drug ruxolitinib suppressed a mouse model of melanoma that is resistant to immune checkpoint blockers.
Noninvasive ventilation is possible in infants at limits of viability. But unlike in slightly older preterm infants, noninvasive ventilation did not show an advantage in infants of 22 weeks-0 days to 23 weeks-6 days gestational age.
Zhang wins $11.2 million NIH PPG grant to improve heart attack recovery through growth of new heart muscle cells.
The deciphering of a new signaling cascade sheds light on how mutations in metabolism cause normal cells to become cancerous.
A novel activity against hypothiocyanite has been found for an E. coli enzyme and homologs enzymes in Streptococcus, Staphylococcus and Bacteroides species, with implications for diseases like cystic fibrosis and inflammatory bowel disease.
The researchers found that ARID1A-deficient bladder cancers are sensitive to combination therapies with the EZH2 inhibitor and inhibitors of PI3K, in a synergistic manner.
These changes, seen in a mouse model, are a likely proteome signature for reductive stress cardiomyopathy. About one in six heart failure patients shows reductive stress, according to a 2018 clinical study.
This monoclonal antibody cocktail is deliverable via a nasal dose, and it is also effective against SARS, MERS and several coronavirus cold viruses. The antibodies are engineered for long-acting effectiveness, potentially lasting a year or more when used in humans.
Page 1 of 44